S3677

On January 15, 2026, Senator Durbin (D-IL) introduced the Dietary Supplement Listing Act of 2026 (S.3677) in the Senate. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. It remains in early legislative stages with no companion bill in the House. The bill mandates that all dietary supplements marketed in the U.S. must be listed with the FDA, including product name, label, ingredient list, and responsible party information. This is an authorization bill with no direct appropriations — it establishes a regulatory requirement but does not allocate government funding. The bill's primary market effect would be increasing regulatory compliance costs for dietary supplement manufacturers. The listing requirement creates a fixed cost per SKU for label submission and maintenance. Companies with large supplement portfolios and thinner margins face the greatest earnings risk. Larger CPG companies with existing FDA regulatory infrastructure and diversified product lines can spread these costs more efficiently. In real market data (Yahoo Finance as of 2026-04-30), Herbalife ($HLF) trades at $16.61, near the middle of its 52-week range ($6.45–$20.40). It has shown a 12.84% gain over 30 days, suggesting some positive momentum unrelated to this bill. Kraft Heinz trades at $22.64, near the bottom of its 52-week range ($21.04–$29.19), with a 0.67% 30-day change showing relative stability. Procter & Gamble ($PG) at $147.04 shows minimal near-term movement related to this bill, as its supplement exposure is negligible. The legislative path is long: the bill must be reported out of committee, pass the Senate, pass the House, and be signed into law. Given its early stage, partisan sponsorship (single Democratic sponsor), and no House companion, market impact is currently muted. Passage probability in the 119th Congress is low.